DrugPatentWatch Database Preview
Ge Healthcare Company Profile
» See Plans and Pricing
What is the competitive landscape for GE HEALTHCARE, and when can generic versions of GE HEALTHCARE drugs launch?
GE HEALTHCARE has forty-nine approved drugs.
There are seven US patents protecting GE HEALTHCARE drugs.
There are one hundred and seventeen patent family members on GE HEALTHCARE drugs in thirty-two countries and one hundred and twenty-four supplementary protection certificates in eighteen countries.
Summary for Ge Healthcare
| International Patents: | 117 |
| US Patents: | 7 |
| Tradenames: | 57 |
| Ingredients: | 38 |
| NDAs: | 49 |
| Drug Master File Entries: | 5 |
Drugs and US Patents for Ge Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | VIZAMYL | flutemetamol f-18 | INJECTABLE;INTRAVENOUS | 203137-002 | Oct 25, 2013 | RX | Yes | Yes | 8,691,185 | Start Trial | Start Trial | ||||
| Ge Healthcare | GALLIUM CITRATE GA 67 | gallium citrate ga-67 | INJECTABLE;INJECTION | 017700-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| Ge Healthcare | HYPAQUE-M,90% | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010220-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ge Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | CERETEC | technetium tc-99m exametazime kit | INJECTABLE;INJECTION | 019829-001 | Dec 30, 1988 | 4,615,876 | Start Trial |
| Ge Healthcare | OMNIPAQUE 140 | iohexol | INJECTABLE;INJECTION | 018956-005 | Nov 30, 1988 | 4,021,481 | Start Trial |
| Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020808-001 | Aug 29, 1997 | 5,349,085 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ge Healthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 330861 | Start Trial |
| Israel | 203316 | Start Trial |
| Australia | 2011200667 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ge Healthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2182988 | SPC/GB15/012 | United Kingdom | Start Trial | PRODUCT NAME: FLUTEMETAMOL (18F) OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF; REGISTERED: UK EU/1/14/941 20140826 |
| 1611115 | 574 | Finland | Start Trial | |
| 1611115 | 2015/004 | Ireland | Start Trial | PRODUCT NAME: VIZAMYL-FLUTEMETAMOL (18F); REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
